Efficient induction of minor histocompatibility antigen HA-I-specific cytotoxic T-cells using dendritic cells retrovirally transduced with HA-I-coding cDNA

Biology of Blood and Marrow Transplantation

Volumn 8, Issue 8, 2002, Pages 412-419

  Mutis, Tuna ^a   Ghoreschi, Kamran ^a   Schrama, Ellen ^a   Kamp, Janine ^a   Heemskerk, Mirjam ^a   Falkenburg, J H Frederik ^a   Wilke, Martina ^a   Goulmy, Els ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigen presentation; Cytotoxic T cells; Dendritic cells; Immunotherapy; Minor histocompatibility antigen HA I; Retroviral gene transfer

Indexed keywords

COMPLEMENTARY DNA; EPITOPE; HA 1 ANTIGEN; HLA A2 ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN; RETROVIRUS VECTOR; SYNTHETIC PEPTIDE; TETRAMER; UNCLASSIFIED DRUG; HA-1 ANTIGEN; OLIGOPEPTIDE;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC RESTRICTION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CANCER RECURRENCE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GOOD MANUFACTURING PRACTICE; HEMATOPOIETIC SYSTEM; HLA MATCHING; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LEUKEMIA CELL; LIVING DONOR; LYMPHOCYTE CULTURE; STEM CELL TRANSPLANTATION; VIRAL GENE DELIVERY SYSTEM; COMPARATIVE STUDY; CULTURE TECHNIQUE; CYTOLOGY; CYTOTOXICITY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; RETROVIRUS;

ANTIGEN PRESENTATION; CELL CULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DNA, COMPLEMENTARY; EPITOPES, T-LYMPHOCYTE; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; LYMPHOCYTE ACTIVATION; MINOR HISTOCOMPATIBILITY ANTIGENS; OLIGOPEPTIDES; RETROVIRIDAE; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

EID: 0036376216     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2002.v8.pm12234166     Document Type: Article

References (38)

1. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts
2. Graft-versus-leukemia reactions after bone marrow transplantation
3. Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy
4. Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation
5. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens
6. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes
7. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones
8. Minor histocompatibility antigens HA-1-, -2-, and -4-, and HY-specific cytotoxic T-cell clones inhibit human hematopoietic progenitor cell growth by a mechanism that is dependent on direct cell-cell contact
9. Feasibility of immunotherapy of relapsed leukemia with ex vivo- generated cytotoxic T lymphocytes specific for hematopoietic system- restricted minor histocompatibility antigens
10. HLA class I-minor histocompatibility antigen tetramers select cytotoxic T-cells with high avidity to the natural ligand
11. Induction of minor histocompatiblity antigen HA-1-specific cytotoxic T cells for the treatment of leukemia after allogeneic stem cell transplantation
12. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro
13. CD83+ human dendritic cells transfected with tumor peptide cDNA by electroporation induce specific T-cell responses: A potential tool for gene immunotherapy
14. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells
15. Enhanced transgene expression and effective in vivo antitumor immune responses initiated by dendritic progenitors transfected with a nonviral T7 vector expressing a model tumor antigen
16. Dendritic cells transfected with the nef genes of HIV-1 primary isolates specifically activate cytotoxic T lymphocytes from seropositive subjects
17. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses
18. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
19. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: Implications for the clinical use of dendritic cells
20. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity
21. Dendritic cells need T cell help to prime cytotoxic T cell responses to strong antigens
22. Enrichment of an antigen-specific T cell response by retrovirally transduced human dendritic cells
23. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease
24. The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism
25. Generation of antigen-specific CD8+ CTLs from naive precursors
26. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes
27. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells
28. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
29. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
30. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
31. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen
32. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
33. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells
34. Identification of subdominant CTL epitopes of the GP100 melanoma- associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells
35. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
36. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy
37. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
38. Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies